Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Aurisco Pharmaceutical Co., Ltd. specializes in the development and commercialization of innovative biopharmaceuticals, particularly in oncology and autoimmune diseases. The company has a strong presence in the Chinese market and leverages its proprietary drug delivery technologies to enhance therapeutic efficacy, setting it apart from competitors.
Aurisco generates revenue primarily through the sale of patented biopharmaceuticals, with a focus on high-margin oncology products. The company's competitive advantages include a robust R&D pipeline, strategic partnerships with research institutions, and proprietary drug delivery systems that improve patient outcomes.
Regulatory approvals for new drugs, particularly in oncology
Partnership announcements with global pharmaceutical companies
Clinical trial results that exceed market expectations
Market expansion efforts in Southeast Asia
Regulatory changes that could impact drug approval processes
Technological disruptions in drug development methodologies
Emergence of generic competitors for existing products
Increased R&D spending by larger pharmaceutical companies
Potential liquidity risks if cash flow does not meet expectations
Rising operational costs impacting margins
moderate - The biotechnology sector is somewhat insulated from economic downturns, but overall healthcare spending can be impacted by GDP fluctuations.
Higher interest rates could increase financing costs for R&D and impact valuations, especially for growth-oriented biotech firms like Aurisco.
minimal - Aurisco's low debt-to-equity ratio (0.36) indicates limited reliance on external financing.
growth - Investors are likely attracted to Aurisco for its potential high growth from innovative therapies.
high - The stock has shown significant volatility, as evidenced by its recent 1-year return of -16.1%.
